These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 17697200)

  • 1. One-week acid suppression trial in uninvestigated dyspepsia patients with epigastric pain or burning to predict response to 8 weeks' treatment with esomeprazole: a randomized, placebo-controlled study.
    van Zanten SV; Flook N; Talley NJ; Vakil N; Lauritsen K; Bolling-Sternevald E; Persson T; Björck E; Svedberg LE;
    Aliment Pharmacol Ther; 2007 Sep; 26(5):665-72. PubMed ID: 17697200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?
    Talley NJ; Vakil N; Lauritsen K; van Zanten SV; Flook N; Bolling-Sternevald E; Persson T; Björck E; Lind T;
    Aliment Pharmacol Ther; 2007 Sep; 26(5):673-82. PubMed ID: 17697201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial.
    van Zanten SV; Armstrong D; Chiba N; Flook N; White RJ; Chakraborty B; Gasco A
    Am J Gastroenterol; 2006 Sep; 101(9):2096-106. PubMed ID: 16817845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole--results from the STARS II study.
    van Zanten SV; Wahlqvist P; Talley NJ; Halling K; Vakil N; Lauritsen K; Flook N; Persson T; Bolling-Sternevald E;
    Aliment Pharmacol Ther; 2011 Oct; 34(7):714-23. PubMed ID: 21848799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised clinical trial: identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care - a randomised, placebo-controlled study.
    Meineche-Schmidt V; Christensen E; Bytzer P
    Aliment Pharmacol Ther; 2011 Jan; 33(1):41-9. PubMed ID: 21083590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
    Zheng Q; Pan Y; Zhang L; Xiao SD
    Chin J Dig Dis; 2005; 6(4):202-5. PubMed ID: 16246231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs.
    Hawkey CJ; Jones RH; Yeomans ND; Scheiman JM; Talley NJ; Goldstein JL; Ahlbom H; Naesdal J
    Aliment Pharmacol Ther; 2007 Apr; 25(7):813-21. PubMed ID: 17373920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors.
    Hawkey C; Talley NJ; Yeomans ND; Jones R; Sung JJ; Långström G; Naesdal J; Scheiman JM;
    Am J Gastroenterol; 2005 May; 100(5):1028-36. PubMed ID: 15842575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized, placebo-controlled trial.
    Johnson DA; Orr WC; Crawley JA; Traxler B; McCullough J; Brown KA; Roth T
    Am J Gastroenterol; 2005 Sep; 100(9):1914-22. PubMed ID: 16128933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial.
    Flook NW; Moayyedi P; Dent J; Talley NJ; Persson T; Karlson BW; Ruth M
    Am J Gastroenterol; 2013 Jan; 108(1):56-64. PubMed ID: 23147520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis.
    Schneider H; Van Rensburg C; Schmidt S; Aboo N; Makela H; Nauclér E; Hallerback B; Svedberg LE
    Digestion; 2004; 70(4):250-6. PubMed ID: 15687727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.
    Gold BD; Gunasekaran T; Tolia V; Wetzler G; Conter H; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):520-9. PubMed ID: 18030228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study.
    Zeng J; Zuo XL; Li YQ; Wei W; Lv GP
    Eur J Clin Pharmacol; 2007 Jun; 63(6):529-36. PubMed ID: 17468863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.
    Sánchez-Delgado J; García-Iglesias P; Castro-Fernández M; Bory F; Barenys M; Bujanda L; Lisozain J; Calvo MM; Torra S; Gisbert JP; Calvet X
    Aliment Pharmacol Ther; 2012 Jul; 36(2):190-6. PubMed ID: 22591220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
    Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose versus low-dose esomeprazole-based triple therapy for Helicobacter pylori infection.
    Hsu PI; Lai KH; Wu CJ; Tseng HH; Tsay FW; Peng NJ; Chen TA; Chuah SK; Lin WS; Lo GH
    Eur J Clin Invest; 2007 Sep; 37(9):724-30. PubMed ID: 17696962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin.
    Yeomans N; Lanas A; Labenz J; van Zanten SV; van Rensburg C; Rácz I; Tchernev K; Karamanolis D; Roda E; Hawkey C; Nauclér E; Svedberg LE
    Am J Gastroenterol; 2008 Oct; 103(10):2465-73. PubMed ID: 18637091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: results from two randomized, parallel-group, placebo-controlled trials.
    Cryer BL; Sostek MB; Fort JG; Svensson O; Hwang C; Hochberg MC
    Ann Med; 2011 Dec; 43(8):594-605. PubMed ID: 22017620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients.
    Tulassay Z; Stolte M; Sjölund M; Engstrand L; Butruk E; Malfertheiner P; Dite P; Tchernev K; Wong BC; Gottlow M; Eklund S; Wrangstadh M; Nagy P
    Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):526-36. PubMed ID: 18467912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease.
    Pace F; Negrini C; Wiklund I; Rossi C; Savarino V;
    Aliment Pharmacol Ther; 2005 Aug; 22(4):349-56. PubMed ID: 16098002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.